ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Venetoclax Plus Low-Dose Cytarabine Safe and Effective in Older Patients With Acute Myeloid Leukemia

The combination of the selective BCL-2 inhibitor venetoclax and low-dose cytarabine (LDAC) is a safe, effective option in older patients with acute myeloid leukemia...

ASH 2014 Annual Meeting Preview: The Rising Cost of Medical Care

Understanding the Problems and Exploring Solutions Health-care spending in the United States is a growing problem: in 2011, health-care spending was estimated at $2.7 trillion,...

2014 ASH Annual Meeting: Late But Certainly Not Least…

This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.